Cancer patient getting treatmentEmerging therapies for cancer not only promise greater survivalrates, but also potentially less costs as they require far lesstime to do their job, according to the report. (Photo:Shutterstock)

Considering that more than a third of Americans will be diagnosed with cancer at some point in theirlifetime, and injectable drugs for cancer are among the mostexpensive partly due to lengthy treatments, it's no surprise thatcancer continues to be the costliest stop-loss claim forself-insured employers, according to the 2019 Sun Life Stop-Loss Research Report: High-cost claimsand injectable drug trends.

But there's good news: emerging therapies for cancer not onlypromise greater survival rates, but also potentially less costs asthey require far less time to do their job, according to thereport.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Katie Kuehner-Hebert

Katie Kuehner-Hebert is a freelance writer based in Running Springs, Calif. She has more than three decades of journalism experience, with particular expertise in employee benefits and other human resource topics.